TuHURA Biosciences, Inc./NV Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | — | — | -$7.1M | — | — | -$0.14 |
| Q2 FY202510-Q · 2025-06-30 | — | — | -$9.5M | — | — | -$0.21 |
| Q1 FY202510-Q · 2025-03-31 | — | — | -$6.7M | — | — | -$0.15 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $25.7M | $8.9M | $2.7M | $16.8M |
| Q2 FY202510-Q | $34.6M | $15.2M | $8.5M | $146.4M |
| Q1 FY202510-Q | $14.6M | $4.8M | $6.2M | $9.9M |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | — | -$7.1M | — | 51,254,789 |
| Q2 FY202510-Q | — | -$9.5M | — | 49,913,946 |
| Q1 FY202510-Q | — | -$6.7M | — | 43,680,396 |
Filings
(4)Methodology
Every figure on this page is pulled directly from TuHURA Biosciences, Inc./NV's own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].